Progression of classic Kaposi's sarcoma with rituximab - 21/08/11
Boston, Massachusetts
Abstract |
Rituximab is a monoclonal antibody directed against the CD20 antigen of B cells and is being used increasingly for treatment of antibody-mediated autoimmune diseases. We observed the rapid progression of Kaposi's sarcoma after our patient received rituximab for autoimmune hemolytic anemia. We postulate that by very specifically depleting B cells, rituximab affects T-cell function (eliminating B- and T-cell interactions), resulting in impaired T-cell–mediated immunity. Dermatologists should use caution when offering rituximab for off-label use.
Le texte complet de cet article est disponible en PDF.Plan
Funding sources: None. Conflict of interest: None. Presented as a poster at the meeting of the New England Dermatological Society, December 4, 2004. |
Vol 53 - N° 1
P. 155-157 - juillet 2005 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?